|
A randomized, controlled, open label phase II study of erlotinib (E) with or without the MET antibody emibetuzumab (Emi) as first-line treatment for EGFRmt non-small cell lung cancer (NSCLC) patients who have disease control after an 8-week lead-in treatment with erlotinib. |
|
|
Research Funding - Lilly (Inst) |
|
|
Research Funding - Lilly (Inst) |
|
|
Research Funding - Lilly (Inst) |
|
|
Consulting or Advisory Role - AstraZeneca; Merck Sharp & Dohme; Pfizer |
Travel, Accommodations, Expenses - Bristol-Myers Squibb; Janssen |
|
|
Research Funding - Lilly (Inst) |
|
|
Research Funding - Lilly (Inst) |
|
|
Research Funding - Lilly (Inst) |
|
|
No Relationships to Disclose |
|
|
No Relationships to Disclose |
|
|
Research Funding - Lilly (Inst) |
|
|
Research Funding - Lilly (Inst) |
|
|
No Relationships to Disclose |
|
|
|
Stock and Other Ownership Interests - Lilly |
Patents, Royalties, Other Intellectual Property - Lilly |
Travel, Accommodations, Expenses - Lilly |
|
|
|
Stock and Other Ownership Interests - Lilly |
Patents, Royalties, Other Intellectual Property - Lilly |
Travel, Accommodations, Expenses - Lilly |
|
|
|
Stock and Other Ownership Interests - Lilly |
Patents, Royalties, Other Intellectual Property - Lilly |
Travel, Accommodations, Expenses - Lilly |
|
|
|
Stock and Other Ownership Interests - Lilly |
Patents, Royalties, Other Intellectual Property - Lilly |
Travel, Accommodations, Expenses - Lilly |
|
|
|
Stock and Other Ownership Interests - Lilly |
Patents, Royalties, Other Intellectual Property - Lilly |
Travel, Accommodations, Expenses - Lilly |
|
|
|
Stock and Other Ownership Interests - Lilly |
Patents, Royalties, Other Intellectual Property - Lilly |
Travel, Accommodations, Expenses - Lilly |
|
|
Research Funding - Lilly (Inst) |